Pharmacotherapy of acute respiratory distress syndrome

Bibliography

• ASHBAUGH DG, BIGELOW DB, PETTY TL, LEVINE BE: Acute respiratory distress in adults. Lancet (1967):319–323.
   PubMed Web of Science ®Google Scholar
• MILBERG JA, DAVIS DR, STEINBERG KP, HUDSON LD: Improved survival of patients with acute respiratory distress syndrome (ARDS):1983-1993. JAMA (1995) 273:306–309.
   PubMed Web of Science ®Google Scholar
• JARDIN F, FELLAHI JL, BEAUCHET A, VIEILLARD-BARON A, LOUBIERES Y, PAGE B: Improved prognosis of acute respiratory distress syndrome 15 years on. Intensive Care Med. (1999) 25:936–941.
   PubMedGoogle Scholar
• WARE LB, MATTHAY MA: The acute respiratory distress syndrome. N Engl. Med. (2000) 342:1334–1349.
   PubMed Web of Science ®Google Scholar
• •This paper provides a comprehensive discussion of our current understanding of the various stages of the pathophysiology of ARDS. An overview of treatment strategies is also presented.
   Google Scholar
• VINCENT JL, BRASE R, SANTMAN F et al.: A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin El (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. (2001) 27:1578–1583.
   PubMed Web of Science ®Google Scholar
• BROWER RG, WARE LB, BERTHIAUME Y, MATTHAY MA: Treatment of ARDS. Chest (2001) 120:1347–1367.
   PubMed Web of Science ®Google Scholar
• •This is the most recent review of actual and potential therapeutic options for ARDS, which complements previous review papers.
   Google Scholar
• KOLLEF MH, SCHUSTER DP: The acute respiratory distress syndrome. N Engl. J. Med. (1995) 332:27–37.
   PubMed Web of Science ®Google Scholar
• MEADE MO, HERRIDGE MS: An evidence-based approach to acute respiratory distress syndrome. Respii: Care (2001) 46:1368–1376.
   PubMedGoogle Scholar
• DREYFUSS D, SAUMON G: Evidence-based medicine or fuzzy logic: what is best for ARDS management? Intensive Care Med. (2002) 28:230–234.
   Google Scholar
• MCINTYRE RC JR, PULIDO EJ, BENSARD DD, SHAMES BD, ABRAHAM E: Thirty years of clinical trials in acute respiratory distress syndrome. Grit. Care Med. (2000) 28:3314–3331.
   PubMedGoogle Scholar
• •The paper systematically reviews various therapeutic strategies for ARDS in terms of published human clinical trials. In addition, the authors provided a grading for the quality of evidence available.
   Google Scholar
• LESUR O, BERTHIAUME Y, BLAISE G et al.: Acute respiratory distress syndrome: 30 years later. Can. Respir: J. (1999) 6:71–86.
   Google Scholar
• HITE RD, MORRIS PE: Acute respiratorydistress syndrome: pharmacological treatment options in development. Drugs (2001) 61:897–907.
   PubMed Web of Science ®Google Scholar
• ALBERTSON TE, MERELICH GP: Pharmacological adjuncts to mechanical ventilation in acute respiratory distress syndrome. Crit. Care Gin. (1998) 14:581–610.
   Google Scholar
• TAEUSCH HW:Treatment of acute (Adult) respiratory distress syndrome. The holy grail of surfactant therapy. Biol. Neonate (2000) 77:2–8.
   PubMedGoogle Scholar
• KWO JBLM: Ancillary therapies for acute respiratory distress syndrome. Int. Anesthesia Clin. (1999) 37:65–83.
   PubMedGoogle Scholar
• LEWIS JS: Surfactant and the acute respiratory distress syndrome (ARDS). Critical care rounds. Can. Grit. Care So (2001) 2:1–6.
   Google Scholar
• ANZUETO A, BAUGHMAN RP, GUNTUPALLI KK et al.: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl. J. Med. (1996) 334:1417–1421.
   PubMed Web of Science ®Google Scholar
• •This large-scale, randomised, controlled trial, despite its negative results, may still provide further insight into refinement for future studies for a therapy of proven benefits for paediatric but not adult ARDS.
   Google Scholar
• SPRAGG R, LEWIS JVVWRF: Treatment of ARDS with rSP-C surfactant. Am. Respir. Grit. Care Med. (2002) 161:A47.
   Google Scholar
• GREGORY TJ, STEINBERG KP, SPRAGG R et al: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. I Respir. Grit. Care Med. (1997) 155:1309–1315.
   PubMed Web of Science ®Google Scholar
• SPRAGG RG, LEWIS JF, RATHGEB F, HAFNER D, SEEGER W: Intratracheal instillation of rSP-C surfactant improves oxygenation in patients with ARDS. Am. Respir. Grit. Care Med. (2002) 165:A22.
   PubMedGoogle Scholar
• ITO Y, VELDHUIZEN RA, YAO LJ, MCCAIG LA, BARTLETT AJ, LEWIS IF: Ventilation strategies affect surfactant aggregate conversion in acute lung injury. Am. I Respir. Crit. Care Med. (1997) 155:493–499.
   PubMed Web of Science ®Google Scholar
• DELLINGER RP, ZIMMERMAN JL, TAYLOR RW et al: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized Phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Grit. Care Med. (1998) 26:15–23.
   Google Scholar
• LUNDIN S, MANG H, SMITHIES M, STENQVIST O, FROSTELL C: Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. (1999) 25:911–919.
   PubMed Web of Science ®Google Scholar
• DUPONT H, LE CORRE F, FIEROBE L et al: Efficiency of inhaled nitric oxide as rescue therapy during severe ARDS: survival and factors associated with the first response. Crit. Care (1999) 14:107–113.
   Google Scholar
• CUTHBERTSON BH, GALLEY HF, WEBSTER NR: Effect of inhaled nitric oxide on key mediators of the inflammatory response in patients with acute lung injury. Crit. Care Med. (2000) 28:1736–1741.
   PubMedGoogle Scholar
• THE ARDS NETWORK: Ventilation withlower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Eng] I Med. (2000) 342:1301–1308.
   PubMed Web of Science ®Google Scholar
• •This multi-centre, randomised, controlled trial is the first to demonstrate a positive effect for an intervention in ARDS and should to lead to significant practice changes. This paper qualifies as a landmark paper for all future clinical trials involving ventilatory strategies for ARDS.
   Google Scholar
• RIALP G, BETBESE Al, PEREZ-MARQUEZ M, MANCEBO J: Short-term effects of inhaled nitric oxide and prone position in pulmonary and extrapulmonary acute respiratory distress syndrome. Am. Respir. Grit. Care Med. (2001) 164:243–249.
   PubMedGoogle Scholar
• PROST IF, DESCHE P, JARDIN F, MARGAIRAZ A: Comparison of the effects of intravenous almitrine and positive end-expiratory pressure on pulmonary gas exchange in adult respiratory distress syndrome. Ear: Respir. (1991) 4:683–687.
   PubMedGoogle Scholar
• REYES A, ROCA J, RODRIGUEZ-ROISIN R, TORRES A, USSETTI P, WAGNER PD: Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome. Am. Rev Respir. D AK (1988) 137:1062–1067.
   PubMed Web of Science ®Google Scholar
• PAYEN DM, GATECEL C, PLAISANCE P: Almitrine effect on nitric oxide inhalation in adult respiratory distress syndrome. Lancet (1993) 341:1664.
   PubMed Web of Science ®Google Scholar
• JOLLIET P, BULPA P, RITZ M, RICOU B, LOPEZ J, CHEVROLET IC: Additive beneficial effects of the prone position, nitric oxide, and almitrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome. Crit. Care Med. (1997) 25:786–794.
   PubMed Web of Science ®Google Scholar
• PAPAZIAN L, ROCH A, BREGEON F et al.: Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome. Am. Respir. Crit. Care Med. (1999) 160:473–479.
   PubMedGoogle Scholar
• WYSOCKI M, DELCLAUX C, ROUPIE E et al: Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome. Intensive Care Med. (1994) 20:254–259.
   PubMedGoogle Scholar
• GALLART L, LU Q, PUYBASSET L, UMAMAHESWARA RAO GS, CORIAT P, ROUBY II: Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. The NO Almitrine Study Group. Am. I Respir. Crit. Care Med. (1998) 158:1770–1777.
   PubMed Web of Science ®Google Scholar
• HOLCROFT JW, VASSAR MI, WEBER CI: Prostaglandin El and survival in patients with the adult respiratory distress syndrome. A prospective trial. Ann. Surg. (1986) 203:371–378.
   PubMedGoogle Scholar
• MEYER J, THEILMEIER G, VAN AKEN H et al: Inhaled prostaglandin El for treatment of acute lung injury in severe multiple organ failure. Anesth. Analg. (1998) 86:753–758.
   PubMed Web of Science ®Google Scholar
• DOMENIGHETTI G, STRICKER H, WALDISPUEHL B: Nebulized prostacyc lin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Grit. Care Med. (2001) 29:57–62.
   PubMed Web of Science ®Google Scholar
• MAX M, KUHLEN R, DEMBINSKI R, ROSSAINT R: Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension. Intensive Care Med. (1999) 25:1147–1154.
   PubMedGoogle Scholar
• SCHERMULY RT, KRUPNIK E, TENOR H et al: Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Ain. J. Respir. Crit. Care Med. (2001) 164:1694–1700.
   PubMed Web of Science ®Google Scholar
• SCHERMULY RT, ROEHL A, WEISSMANN N et al.: Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am. I Physiol Lung Cell MM. Physiol (2001) 281:L1361–L1368.
   Google Scholar
• KUHLEN R, WALBERT E, FRANKEL P, THADEN S, BEHRENDT W, ROSSAINT R: Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with acute respiratory distress syndrome. Intensive Care Med. (1999) 25:752–754.
   PubMedGoogle Scholar
• FURUE S, MIKAWA K, NISHINA K et al.: Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit. Care Med. (2001) 29:719–727.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, WHEELER AP, RUSSELL JA et at The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Eng] I Med. (1997) 336:912–918.
   PubMed Web of Science ®Google Scholar
• ESPOSITO AL: Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia. Am. Rev Respir. Dis. (1984) 130:857–862.
   PubMedGoogle Scholar
• RICE GC, BROWN PA, NELSON RI, BIANCO JA, SINGER JW, BURSTEN S: Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc. Natl. Acad. Sci. USA (1994) 91:3857–3861.
   PubMed Web of Science ®Google Scholar
• Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit. Care Med. (2002) 30:1–6.
   Google Scholar
• SLOTMAN GJ, BURCHARD KW, D'AREZZO A, GANN DS: Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J. Trauma (1988) 28:648–654.
   PubMed Web of Science ®Google Scholar
• YU M, TOMASA G: A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit. Care Med. (1993) 21:1635–1642.
   PubMed Web of Science ®Google Scholar
• THE ARDS NETWORK: Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA (2000) 283:1995–2002.
   PubMedGoogle Scholar
• •Despite the lack of positive results, this paper nevertheless is important given its rigourous design and large sample size that are not frequently seen with clinical trials in critical care.
   Google Scholar
• SINUFF T, COOK DJ, PETERSON JC, FULLER HD: Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis." Grit. Care (1999) 14:1–6.
   Google Scholar
• HOGG JC, DOERSCHUK CM: Leukocyte traffic in the lung. Ann. Rev Physiol (1995) 57:97–114.
   PubMed Web of Science ®Google Scholar
• ALBERT RK: Mechanisms of the adult respiratory distress syndrome: selectins. Thorax (1995) 50\(Suppl. 1): S49–S52.
   Google Scholar
• ALBELDA SM, SMITH CW, WARD PA: Adhesion molecules and inflammatory injury. FASEB.I. (1994) 8:504–512.
   PubMed Web of Science ®Google Scholar
• MUKAIDA N, MATSUMOTO T, YOKOI K, HARADA A, MATSUSHIMA K: Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8 (IL-8). Inflainin. Res. (1998) 47\(Suppl. 3):5151–5157.
   Google Scholar
• REMICK DG, GREEN LB, NEWCOMB DE, GARG SJ, BOLGOS GL, CALL DR: CXC chemokine redundancy ensures local neutrophil recruitment during acute inflammation. Am. I Pathol (2001) 159:1149–1157.
   PubMedGoogle Scholar
• KUDOH I, OHTAKE M, NISHIZAWA H et al.: The effect of pentoxifylline on acid-induced alveolar epithelial injury. Anesthesiology (1995) 82:531–541.
   PubMed Web of Science ®Google Scholar
• BURSTEN SL, FEDERIGHI DA, PARSONS P et al.: An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome. Grit. Care Med. (1996) 24:1129–1136.
   PubMedGoogle Scholar
• CARRAWAY MS, WELTY-WOLF KE, KANTROW SP et al.: Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons. Am. J. Respic Grit. Care Med. (1998) 157:938–949.
   PubMedGoogle Scholar
• RIMENSBERGER PC, FEDORKO L, CUTZ E, BOHN DJ: Attenuation of ventilator-induced acute lung injury in an animal model by inhibition of neutrophil adhesion by leumedins (NPC 15669). Grit. Care Med. (1998) 26:548–555.
   PubMedGoogle Scholar
• XU N, RAHMAN A, MINSHALL RD, TIRUPPATHI C, MALIK AB: Beta(2)-Integrin blockade driven by E-selectin promoter prevents neutrophil sequestration and lung injury in mice. Circ. Res. (2000) 87:254–260.
   PubMed Web of Science ®Google Scholar
• WELTY-WOLF KE, CARRAWAY MS, HUANG YC et al.: Antibody to intercellular adhesion molecule 1 (CD54) decreases survival and not lung injury in baboons with sepsis. Am. J. Respic Grit. Care Med. (2001) 163:665–673.
   PubMedGoogle Scholar
• MULLIGAN MS, DESROCHERS PE, CHINNAIYAN AM et al.: ha vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc. Natl. Acad. Sci. USA (1993) 90:11523–11527.
   PubMedGoogle Scholar
• FODA HD, ROLLO EE, BROWN PA et al: Attenuation of oxidant-induced lung injury by the synthetic matrix metalloproteinase inhibitor BB-3103. Ann. New York Acad. Sci. (1999) 878:650–653.
   PubMedGoogle Scholar
• CARNEY DE, MCCANN UG, SCHILLER HJ et al.: Metalloproteinase inhibitor prevents acute respiratory distress syndrome. J. Surg. Res. (2001) 99:245–252.
   PubMed Web of Science ®Google Scholar
• CARNEY DE, LUTZ CJ, PICONE AL etal.: Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation (1999) 100:400–406.
   Google Scholar
• FODA HD, ROLLO EE, DREWS M et al.: Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340). Am. J. Respic Cell MM. Biol. (2001) 25:717–724.
   PubMed Web of Science ®Google Scholar
• JEPSEN S, HERLEVSEN P, KNUDSEN P, BUD MI, KLAUSEN NO: Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit. Care Med. (1992) 20:918–923.
   PubMed Web of Science ®Google Scholar
• SPIES CD, REINHART K, WITT I et al.: Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit. Care Med. (1994) 22:1738–1746.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, WHEELER AP, ARONS MM et al.: A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest (1997) 112:164–172.
   Google Scholar
• DOMENIGHETTI G, SUTER PM, SCHALLER MD, RITZ R, PERRET C: Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J. Grit. Care (1997) 12:177–182.
   Google Scholar
• FAN J, SHEK PN, SUNTRES ZE, LI YH, OREOPOULOS GD, ROTSTEIN OD: Liposomal antioxidants provide prolonged protection against acute respiratory distress syndrome. Surgery(2000) 128:332–338.
   PubMed Web of Science ®Google Scholar
• INOUE S, SUZUKI M, NAGASHIMA Y et al: Transfer of heme oxygenase 1 cDNA by a replication-deficient adenovirus enhances interleukin 10 production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice. Hum. Gene Ther: (2001) 12:967–979.
   Google Scholar
• HASHIBA T, SUZUKI M, NAGASHIMA Y et al.: Adenovirus-mediated transfer of heme oxygenase-1 cDNA attenuates severe lung injury induced by the influenza virus in mice. Gene The]: (2001) 8:1499–1507.
   PubMed Web of Science ®Google Scholar
• STERN M, ULRICH K, ROBINSON C et al.: Pretreatment with cationic lipid-mediated transfer of the Na+KLATPase pump in a mouse model in vivo augments resolution of high permeability pulmonary oedema. Gene Thec (2000) 7:960–966.
   PubMedGoogle Scholar
• FACTOR P, DUMASIUS V, SALDIAS F, SZNAJDER JI: Adenoviral-mediated overexpression of the NA,K-ATPase betal subunit gene increases lung edema clearance and improves survival during acute hyperoxic lung injury in rats. Chest (1999) 116:24S–25S.
   Google Scholar
• SAKUMA T, FOLKESSON HG, SUZUKI S, OKANIWA G, FUJIMURA S, MATTHAY MA: Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am. J. Respic Crit. Care Med. (1997) 155:506–512.
   PubMed Web of Science ®Google Scholar
• CAMPBELL AR, FOLKESSON HG, BERTHIAUME Y, GUTKOWSKA J, SUZUKI S, MATTHAY MA: Alveolar epithelial fluid clearance persists in the presence of moderate left atrial hypertension in sheep. AppL Physiol (1999) 86:139–151.
   PubMedGoogle Scholar
• WARE LB, MATTHAY MA: Alveolar fluidclearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am. .1 Respir. Grit. Care Med. (2001) 163:1376–1383.
   PubMed Web of Science ®Google Scholar
• TIBAYAN FA, CHESNUTT AN, FOLKESSON HG, EANDI J, MATTHAY MA: Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am. J Respir. Grit. Care Med. (1997) 156:438–444.
   PubMedGoogle Scholar
• BARNARD ML, OLIVERA WG, RUTSCHMAN DM, BERTORELLO AM, KATZ Al, SZNAJDER JI: Dopamine stimulates sodium transport and liquid clearance in rat lung epithelium. Am. .1 Respir. Crit. Care Med. (1997) 156:709–714.
   PubMedGoogle Scholar
• MASCLANS JR, BARBERA JA, MACNEE W et al: Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans. Am. .1 Respir. Crit. Care Med. (1996) 154:529–532.
   PubMedGoogle Scholar
• BARNARD JW, SEIBERT AF, PRASAD VR et al: Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a rAMP phosphodiesterase inhibitor. J. Appl. Physiol (1994) 77:774–781.
   PubMed Web of Science ®Google Scholar
• DHINGRA VK, UUSARO A, HOLMES CL, WALLEY KR: Attenuation of lung inflammation by adrenergic agonists in murine acute lung injury. Anesthesiology (2001) 95:947–953.
   PubMedGoogle Scholar
• RAY A, PREFONTAINE KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA (1994) 91:752–756.
   PubMed Web of Science ®Google Scholar
• SCHEINMAN RI, COGS WELL PC, LOFQUIST AK, BALDWIN AS JR: Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science (1995) 270:283–286.
   PubMed Web of Science ®Google Scholar
• AUPHAN N, DID ONATO JA, ROSETTE C, HELMBERG A, KARIN M: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science (1995) 270:286–290.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, LUCE JM, SPRUNG CL et al.: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl. J Med. (1987) 317:1565–1570.
   PubMed Web of Science ®Google Scholar
• LUCE JM, MONTGOMERY AB, MARKS JD, TURNER J, METZ CA, MURRAY JF: Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am. Rev Respir. D AK (1988) 138:62–68.
   PubMed Web of Science ®Google Scholar
• BONE RC, FISHER CJ JR, CLEMMER TP, SLOTMAN GJ, METZ CA: Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest (1987) 92:1032–1036.
   PubMed Web of Science ®Google Scholar
• MEDURI GU, HEADLEY AS, GOLDEN E et al: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA (1998) 280:159–165.
   PubMed Web of Science ®Google Scholar
• •Although a small randomised, controlled trial with methodological concerns, the potentially positive results within this trial nevertheless provided the impetus for the large, ongoing ARDS/Net trial to further evaluate the role of corticosteroids in late ARDS.
   Google Scholar
• PANOS RJ, BAK PM, SIMONET WS, RUBIN JS, SMITH LJ: Intratracheal instillation of keratinocyte growth factor decreases hyperwda-induced mortality in rats../. Clin. Invest. (1995) 96:2026–2033.
   Google Scholar
• WANG Y, FOLKESSON HG, JAYR C, WARE LB, MATTHAY MA: Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy. J Appl. Physiol (1999) 87:1852–1860.
   PubMed Web of Science ®Google Scholar
• VIGET NB, GUERY BP, ADER F et al: Keratinocyte growth factor protects against Pseudomonas aeruginosa-induced lung injury. Am. J. Physiol Lung Cell Ma Physiol (2000) 279:L1199–L1209.
   Google Scholar
• WELSH DA, SUMMER WR, DOBARD EP, NELSON S, MASON CM: Keratinocyte growth factor prevents ventilator-induced lung injury in an ex vivo rat model. Am. J. Respic Crit. Care Med. (2000) 162:1081–1086.
   PubMed Web of Science ®Google Scholar
• OSWARI J, MATTHAY MA, MARGULIES SS: Keratinocyte growth factor reduces alveolar epithelial susceptibility to M vitro mechanical deformation. Am. J Physiol Lung Cell Ma. Physiol (2001) 281:L1068–L1077.
   Google Scholar
• WATERS CM, SAVLA U, PANOS RJ: KGF prevents hydrogen peroxide-induced increases in airway epithelial cell permeability. Am. J Physiol (1997) 272:L681–L689.
   Google Scholar
• DOCKE WD, RAND OW F, SYRBE U etal: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med (1997) 3:678–681.
   PubMed Web of Science ®Google Scholar
• HUSTINX WN, VAN KESSEL CP, HEEZIUS E, BURGERS S, LAMMERS JW, HOEPELMAN IM: Effects of granulocyte colony-stimulating factor (G-CSF) treatment on granulocyte function and receptor expression in patients with ventilator-dependent pneumonia. Clin. Exp. Immunol (1998) 112:334–340.
   PubMedGoogle Scholar
• VOLK HD, REINKE P, DOCKE WD: Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem. Immunol (2000) 74:162–177.
   PubMedGoogle Scholar
• HUSTINX WN, VAN KESSEL CP, HEEZIUS E, BURGERS S, LAMMERS JW, HOEPELMAN IM: Effects of granulocyte colony-stimulating factor (G-CSF) treatment on granulocyte function and receptor expression in patients with ventilator-dependent pneumonia. Clin. Exp. Immunol (1998) 112:334–340.
   PubMedGoogle Scholar
• NELSON S, BELKNAP SM, CARLSON RW et al.: A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect. Dis. (1998) 178:1075–1080.
   PubMedGoogle Scholar
• WUNDERINK R, LEEPER K JR, SCHEIN R et al.: Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest (2001) 119:523–529.
   PubMed Web of Science ®Google Scholar
• INOUE G: Effect of interleukin-10 (IL-10) on experimental LPS-induced acute lung injury. J Infect. Chemothec (2000) 6:51–60.
   PubMedGoogle Scholar
• OSMAN MO, JACOBSEN NO, KRISTENSEN JU et al: IT 9302, a synthetic interleukin-10 agonist, diminishes acute lung injury in rabbits with acute necrotizing pancreatitis. Surgery (1998) 124:584–592.
   PubMed Web of Science ®Google Scholar
• GREENBERGER MJ, STRIETER RM, KUNKEL SL, DANFORTH JM, GOODMAN RE, STANDIFORD TJ: Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. Immunol (1995) 155:722–729.
   Google Scholar
• FISCHER S, LIU M, MACLEAN AA, DE PERROT M et al.: In vivo transtracheal adenovirus-mediated transfer of human interleukin-10 gene to donor lungs ameliorates ischemia-reperfusion injury and improves early posttransplant graft function in the rat. Hum. Gene Thec (2001) 12:1513–1526.
   Google Scholar
• WANG E, SIMARD M, OUELLET N, BERGERON Y, BEAUCHAMP D, BERGERON MG: Modulation of cytokines and chemokines, limited pulmonary vascular bed permeability, and prevention of septicemia and death with ceftriaxone and interleukin-10 in pneumococcal pneumonia. J. Infect. Dis. (2000) 182:1255–1259.
   PubMed Web of Science ®Google Scholar
• MORRISON DF, FOSS DL, MURTAUGH MP: Interleukin-10 gene therapy-mediated amelioration of bacterial pneumonia. Infect. Immun. (2000) 68:4752–4758.
   PubMedGoogle Scholar
• WEBER T, TSCHERNICH H, SITZWOHL C et al: Tromethamine buffer modifies the depressant effect of permissive hypercapnia on myocardial contractility in patients with acute respiratory distress syndrome. Am. I Respic Crit. Care Med. (2000) 162:1361–1365.
   PubMedGoogle Scholar
• MURAKAMI K, OKAJIMA K, UCHIBA M et al.: Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am. Physic]. (1997) 272: L197–L202.
   PubMed Web of Science ®Google Scholar
• WHITE B, SCHMIDT M, MURPHY C et al.: Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br. J. Haematcl. (2000) 110:130–134.
   PubMed Web of Science ®Google Scholar
• WELTY-WOLF KE, CARRAWAY MS, MILLER DL et al.: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am. .1. Respic Crit. Care Med. (2001) 164:1988–1996.
   Google Scholar
• ENKHBAATAR P, OKAJIMA K, MURAKAMI K et al.: Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am. j Respic Crit. Care Med. (2000) 162:1752–1759.
   PubMedGoogle Scholar